“We are pleased with our strong year-over-year revenue growth and continued momentum in international markets,” said David Pidduck, CEO of MediPharm Labs (MEDIF). “While the second quarter included the cost and distraction of a proxy contest, our team remained focused and delivered solid results. I want to thank our shareholders again for their continued support and engagement. We are aligned in our vision to build a profitable, cash flow-positive business, and remain confident in our path forward.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MEDIF:
- MediPharm Labs Poised for Growth Amid Potential U.S. Cannabis Rescheduling
- MediPharm Labs to Announce Q2 2025 Financial Results
- MediPharm Labs Expands CBN Portfolio with New Nighttime Inhaler
- Medipharm Labs announces launch of new Shake & Puff CBN THC inhaler
- MediPharm Labs Announces 2025 Shareholder Meeting Results and Board Changes